Rate Benchmarking
Compare your rates with similar providers.
Select a published rate, define comparable providers, and see where that rate falls in your market.
See a sample rate comparisonHCPCS J2350 (Ocrevus) Fee Schedule
Last Verified: October 2026
Healthcare providers use this code to document and receive reimbursement for visits that address moderate-level medical decision-making, often including multiple diagnoses or prescription management.
Injection, ocrelizumab, 1 mg
| Key Fact | Detail |
|---|---|
| Service Type | Drugs Administered Other than Oral Method Drugs, Administered by Injection |
| Common Place of Service | 11 - Office |
| Complexity Level | Low |
| Medicare Fee Schedule | $60.69 per 1 mg (October 2026 ASP) · View Medicare rates for J2350 |
| Medicaid Fee Schedule | $60.565 median of the 8 states in the free preview · View Medicaid rates for J2350 |
| Medicare Payment Limit | $59.414  |
| WAC Price | Lorem ipsum dolor sit amet consectetur Lorem ipsum dolor sit amet consectetur VisitBuyandBill.com |
| Related NDC Codes | • 50242-0150-01 - OCREVUS (SDV,PF) 30 MG/1 ML |
National average reimbursement for HCPCS J2350 by major payers:
$65.63
$61.50
$67.93
$63.62
Compare published rates across providers.
Choose a payer to see a sample of rates for HCPCS J2350.
HCPCS J2350
5 of 25 sample ratesHigher to lower in this preview
Samantha Allen
Scott & White Clinic
$115.12Published rateDe Valle & Associates Physicians PLLC, Clinica Hispana II
De Valle Associates Physicians PLLC
$60.25Published rateCrockett Clinic LLP
$59.79Published rateMelissa Lane
Inpatient Consultants Of Kansas PA
$58.75Published rateRene Darveaux
Delta Healthcare LLC
$0.10Published rate
Get a free rate benchmark for your specialty.
Choose your state and specialty to build a report from payer-published rates.
Use market rates to prepare your payer proposal.
Payer Contract Negotiation
Draft a fee schedule renegotiation letter.
Use your fee schedule and market benchmarks to set target rates and draft a letter for your payer.
See a sample payer proposalHCPCS J2350 vs. Other Drugs, Administered by Injection Codes
The HCPCS J2350 code is part of the Drugs Administered Other than Oral Method services used for Drugs, Administered by Injection. It represents a moderate-complexity encounter and is one of several codes that vary based on time spent, level of medical decision-making, and documentation requirements.
The HCPCS J2350 code involves more provider time and moderate medical decision-making, unlike lower-level codes that require less time and simpler assessments. It typically includes multiple diagnoses, medication management, or test interpretation, leading to higher reimbursement and more detailed documentation requirements.
| Code | Complexity | Description |
|---|---|---|
| 50242-0150-01-NDC | Moderate | OCREVUS (SDV,PF) 30 MG/1 ML |
| J2329-HCPCS | Low | Injection, ublituximab-xiiy, 1mg |
| J2350-HCPCS | Low | Injection, ocrelizumab, 1 mg |
| J2353-HCPCS | Moderate | Injection, octreotide, depot form for intramuscular injection, 1 mg |
What is a fee schedule?
A fee schedule is a list of fixed prices that healthcare providers charge for specific services, including HCPCS J2350. These prices vary depending on payer type (Medicare, Medicaid, private insurance), geographic location, and provider contracts.
Understanding the J2350 fee schedule helps patients estimate costs and providers optimize billing for accurate reimbursements.
Factors that affect fee schedules
Medicare & Medicaid Rates
Government-set reimbursement amounts
Private Insurance Rates
Negotiated rates between providers and insurance companies
Geographic Location
Costs may be higher in urban areas.
Provider Type
Hospital providers may have different rates than private practice.
FREE SAMPLE MARKET COMPARISON
Let's review your payer contracts side-by-side with the market.
Bring your top codes (like HCPCS J2350) and we'll show you how you compare in 15 minutes or less.